RMTG · Regenerative Medical Technology Group Inc.
$0.08
-0.02 (-19.90%)
At close · Sep 2
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of approximately $79,484,265 and a working capital deficit of $40,328,417 as of June 30, 2026, and future losses are anticipated. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Market Cap
$1.34M
Shares
13.74M
RMTG metrics
53 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.08
Market cap
$1.34M
Price action
19 metricsPrice change (1W)
+2.6%
Price change (30D)
+43.2%
Price change (3M)
+186.8%
Price change (6M)
+225.0%
Price change (YTD)
+99.0%
Price change (1Y)
+33.6%
Trailing year
Price change (5Y)
-27.8%
52-week high
$0.12
52-week low
$0.02
Change from 52-week high
-18.8%
Change from 52-week low
+415.9%
Annualized volatility
365.2%
Beta
2.6
RSI (14D)
57.6
Price vs SMA 50
+50.4%
Price vs SMA 200
+97.3%
Avg volume (3M)
114,907
Relative volume
0.7
Average dollar volume
$8,083
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
13.74M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 702.8%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
5.0
reciprocal yield 20.0%
Earnings yield
-701.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
59.8%
Operating margin
0.5%
Trailing 12 months
Net margin
-99.7%
Gross profit (TTM)
$5.63M
Operating profit (TTM)
$43,725
Net income (TTM)
−$9.39M
Trailing 12 months
Diluted EPS (TTM)
$-0.73
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+309.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$9.41M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.5%
Year over year · more shares
Revenue CAGR (3Y)
+49.4%
Revenue CAGR (5Y)
+147.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-160.5%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
$406,650
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
0.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.32M
Total assets
$5.85M
Total debt
$4
Cash flow & spend
7 metricsOperating cash flow (TTM)
$268,563
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
37 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged